Evaluation of the pharmacist’s follow-up in the management of chronic pain

Effect of pharmacotherapeutic follow-up in the management of chronic pain: a randomized clinical trial.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

REBEC

Registry ID

RBR-3xf65s5

Enrollment

240

Registered

2026-03-19

Start date

2026-04-01

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fibromyalgia

Interventions

This is a four-arm, partially blinded, randomized controlled trial conducted at the Rheumatology Outpatient Clinic of the University Hospital of Sergipe (Hospital Universitário - Universidade Federal

s allocation will be revealed sequentially, only after confirmation of eligibility and formal signing of the Informed Consent Form (ICF). The seed value used by the software to initiate sequence gener

Eligibility

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients diagnosed with osteoarthritis, gout, systemic lupus erythematosus, rheumatoid arthritis, and fibromyalgia; patients of both sexes; aged 18 years or older; currently using prescribed pharmacological treatment for these conditions for at least one month.

Exclusion criteria

Exclusion criteria: Patients with severe psychiatric disorders; cancer; pregnant women; patients without access to the WhatsApp® application; patients currently participating in other clinical trials evaluating the same outcomes of this study.

Design outcomes

Primary

Measure	Time frame
To evaluate pain intensity in patients with chronic pain before and after pharmaceutical interventions; assessed using the Numerical Rating Scale (Numerical Rating Scale - 0 to 10); reductions in score will be observed, with a reduction of 10 to 20% considered of minimal clinical importance, a reduction equal to or greater than 30% considered moderately important, and a reduction equal to or greater than 50% considered substantially important. To evaluate the lifestyle of participants before and after pharmaceutical interventions; assessed using the Brazilian adaptation of the Fantastic Lifestyle Questionnaire; changes in total score will be observed, classified into five categories: "excellent" (85 to 100 points), "very good" (70 to 84 points), "good" (55 to 69 points), "regular" (35 to 54 points), and "needs improvement" (0 to 34 points). To evaluate the quality of life of participants before and after pharmaceutical interventions; assessed using condition-specific instruments: Fibromyalgia Impact Questionnaire Revised - Brasil (Questionário de Impacto da Fibromialgia Revisado para o Brasil) for fibromyalgia (score from 0 to 100, with scores above 50 indicating a major disease impact), Brasil-Arthritis Impact Measurement Scales 2 (Arthritis Impact Measurement Scales 2 - Brasil) for rheumatoid arthritis (score from 0 to 120, where higher scores indicate greater negative impact), Western Ontario and McMaster Universities Osteoarthritis Index (Índice de Osteoartrite das Universidades de Western Ontario e McMaster) for osteoarthritis (pain subscale 0 to 20, stiffness 0 to 8, and physical function 0 to 68), and Short Form 36 Health Survey (Formulário Curto de Pesquisa de Saúde com 36 itens) for systemic lupus erythematosus and gout (score from 0 to 100, where higher values indicate better health status).	—

Measure

Time frame

To evaluate pain intensity in patients with chronic pain before and after pharmaceutical interventions; assessed using the Numerical Rating Scale (Numerical Rating Scale - 0 to 10); reductions in score will be observed, with a reduction of 10 to 20% considered of minimal clinical importance, a reduction equal to or greater than 30% considered moderately important, and a reduction equal to or greater than 50% considered substantially important. To evaluate the lifestyle of participants before and after pharmaceutical interventions; assessed using the Brazilian adaptation of the Fantastic Lifestyle Questionnaire; changes in total score will be observed, classified into five categories: "excellent" (85 to 100 points), "very good" (70 to 84 points), "good" (55 to 69 points), "regular" (35 to 54 points), and "needs improvement" (0 to 34 points). To evaluate the quality of life of participants before and after pharmaceutical interventions; assessed using condition-specific instruments: Fibromyalgia Impact Questionnaire Revised - Brasil (Questionário de Impacto da Fibromialgia Revisado para o Brasil) for fibromyalgia (score from 0 to 100, with scores above 50 indicating a major disease impact), Brasil-Arthritis Impact Measurement Scales 2 (Arthritis Impact Measurement Scales 2 - Brasil) for rheumatoid arthritis (score from 0 to 120, where higher scores indicate greater negative impact), Western Ontario and McMaster Universities Osteoarthritis Index (Índice de Osteoartrite das Universidades de Western Ontario e McMaster) for osteoarthritis (pain subscale 0 to 20, stiffness 0 to 8, and physical function 0 to 68), and Short Form 36 Health Survey (Formulário Curto de Pesquisa de Saúde com 36 itens) for systemic lupus erythematosus and gout (score from 0 to 100, where higher values indicate better health status).

—

Secondary

Measure	Time frame
To evaluate pharmacological treatment adherence among participants before and after pharmaceutical interventions; assessed using the General Medication Adherence Scale (Escala Geral de Adesão à Medicação) translated and validated in Brazil, composed of 11 questions on a Likert scale from 0 to 3; adherence categories will be observed: high adherence (30 to 33 points), good adherence (27 to 29 points), partial adherence (17 to 26 points), low adherence (11 to 16 points), and poor adherence (0 to 10 points). To evaluate drug-related problems identified during pharmaceutical interventions; assessed using the classification proposed by Cipolle and colleagues (2004), categorized according to necessity, effectiveness, safety, and compliance, with associated diseases classified according to the International Statistical Classification of Diseases and Related Health Problems - tenth revision (ICD-10); the number and type of drug-related problems identified and resolved throughout the study will be observed. To evaluate participant satisfaction with the pharmaceutical care received at the end of the interventions; assessed using the Net Promoter Score (Pontuação Líquida do Promotor) method, on a scale from 0 to 10; the proportions of participants classified as "promoters" (score of 9 or 10), "passively satisfied" (score of 7 or 8), and "detractors" (score of 0 to 6) will be observed.	—

Measure

Time frame

To evaluate pharmacological treatment adherence among participants before and after pharmaceutical interventions; assessed using the General Medication Adherence Scale (Escala Geral de Adesão à Medicação) translated and validated in Brazil, composed of 11 questions on a Likert scale from 0 to 3; adherence categories will be observed: high adherence (30 to 33 points), good adherence (27 to 29 points), partial adherence (17 to 26 points), low adherence (11 to 16 points), and poor adherence (0 to 10 points). To evaluate drug-related problems identified during pharmaceutical interventions; assessed using the classification proposed by Cipolle and colleagues (2004), categorized according to necessity, effectiveness, safety, and compliance, with associated diseases classified according to the International Statistical Classification of Diseases and Related Health Problems - tenth revision (ICD-10); the number and type of drug-related problems identified and resolved throughout the study will be observed. To evaluate participant satisfaction with the pharmaceutical care received at the end of the interventions; assessed using the Net Promoter Score (Pontuação Líquida do Promotor) method, on a scale from 0 to 10; the proportions of participants classified as "promoters" (score of 9 or 10), "passively satisfied" (score of 7 or 8), and "detractors" (score of 0 to 6) will be observed.

—

Countries

Contacts

Public ContactCristiani Isabel Walker

Universidade Federal de Sergipe

bandewalk@hotmail.com+55(79)91935667

Outcome results

None listed

Source: REBEC (via WHO ICTRP) · Data processed: Apr 4, 2026